Key regions: Australia, Japan, United States, Germany, Europe
Anti-coagulants are a crucial component in the treatment of various medical conditions such as deep vein thrombosis, pulmonary embolism, and stroke prevention. In Czechia, the market for anti-coagulants has been witnessing significant growth in recent years.
Customer preferences: Patients in Czechia have shown a growing preference for direct oral anticoagulants (DOACs) over traditional anticoagulants such as warfarin. DOACs offer several advantages over warfarin, including fewer interactions with other medications and foods, less frequent monitoring, and a lower risk of bleeding.
Trends in the market: The market for anti-coagulants in Czechia has been growing steadily due to an increase in the prevalence of medical conditions that require anti-coagulant treatment. Additionally, the introduction of new DOACs in the market has further fueled the growth of the market. The market is expected to continue to grow as the population ages and the prevalence of medical conditions such as atrial fibrillation and deep vein thrombosis increases.
Local special circumstances: Czechia has a well-developed healthcare system that provides universal coverage to its citizens. The country has a high standard of medical care, and patients have easy access to medical facilities and treatments. Additionally, the government has implemented policies to encourage the use of DOACs over traditional anticoagulants, which has further boosted the growth of the market.
Underlying macroeconomic factors: The Czech economy has been growing steadily in recent years, with a focus on innovation and technology. The country has a highly educated workforce, and the government has implemented policies to encourage entrepreneurship and investment in research and development. These factors have contributed to the growth of the pharmaceutical industry in Czechia, which includes the anti-coagulants market. Additionally, the country's membership in the European Union has facilitated the import and export of pharmaceutical products, further contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
